Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401915 | 0.87 | ALDH1A1 (0.56) | SMN1; SMN2MAPTHTTGAATHRB | |
| SCHEMBL18691800 | 0.86 | HTT (0.62) | SMN1; SMN2MAPTHTTGAATHRB | |
| SCHEMBL404263 | 0.85 | ALDH1A1 (0.76) | SMN1; SMN2MAPTHTTGAATHRB | |
| SCHEMBL17249588 | 0.85 | ALDH1A1 (0.76) | SMN1; SMN2MAPTHTTGAATHRB | |
| SCHEMBL17249593 | 0.85 | ALDH1A1 (0.76) | SMN1; SMN2MAPTHTTGAATHRB | |
| SCHEMBL10029261 | 0.85 | ALDH1A1 (0.76) | SMN1; SMN2MAPTHTTGAATHRB | |
| SCHEMBL17676791 | 0.84 | ALDH1A1 (0.53) | SMN1; SMN2MAPTHTTGAATHRB | |
| SCHEMBL10029243 | 0.84 | ALDH1A1 (0.53) | SMN1; SMN2MAPTHTTGAATHRB | |
| SCHEMBL704579 | 0.83 | ALDH1A1 (0.52) | SMN1; SMN2MAPTHTTGAATHRB | |
| SCHEMBL21024667 | 0.78 | ALDH1A1 (0.55) | SMN1; SMN2MAPTHTTGAATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039504-B2 | heating a mixture of anti-tricyclo[3.2.2.0]non-6-ene-endo-8, endo-9-dicarboxylic acid anhydride, 4-(trifluoromethyl)benzhydrazide, and ethanol at reflux, concetrating and recrystallizing; 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide | SIGA TECHNOLOGIES, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | SMN1; SMN2 3328/4885MAPT 2433/4885HTT 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.